|
at 16:30 |
|
|
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data highlight multiple ascending dose safety, bioactivity...
|
|
at 16:30 |
|
|
Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") today announced results for its first quarter ended March 31, 2024, and the declaration of a cash dividend.
For the first quarter ended March 31, 2024, revenue increased...
|
|
at 16:30 |
|
|
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2024 financial results on Wednesday, May 8, 2024. Karyopharm's management team will host a...
|
|
at 16:20 |
|
|
Sangamo Therapeutics, Inc. , a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.
The company will hold a conference...
|
|
at 16:15 |
|
|
GE HealthCare , is announcing that its Vice President and Chief Financial Officer, Jay Saccaro will be presenting at the following upcoming investor conferences.
Bank of America Securities 2024 Healthcare Conference in Las Vegas ? May 14, 2024 at...
|
|
at 16:15 |
|
|
Revance Therapeutics, Inc. , today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT...
|
|
|
